Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
Official title: Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial
Funded at University of California, San Francisco · NIH-11523069 · Data updated 2026-11-12
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $58,047 |
| NIH project number | 3UG1EY038172-01S2 |
| Project ID | NIH-11523069 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children aged 0-11 years with JIA-associated uveitis who have achieved stable disease on adalimumab.
✕Less likely to help
Patients with unstable disease or intolerance to adalimumab may not benefit from dose reduction.
What this research studies
Children with JIA-associated uveitis can suffer vision problems from ongoing inflammation. This trial builds on prior findings that stopping or reducing adalimumab can lead to relapse, and it explores a safer, cost-conscious dosing approach. The study involves careful monitoring of disease activity, adverse events, and quality of life while adjusting dose frequency. Parents and clinicians will work together to determine if a lighter dosing schedule maintains control of uveitis in young patients.
Why it matters
Potential benefit: If successful, the dose-adjustment strategy could maintain eye inflammation control while reducing treatment burden and costs for families.
How similar studies have gone: Previous trials showed relapse upon stopping adalimumab but relapse often responds to restarting treatment, suggesting dosing adjustments may be feasible.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Acharya, Nisha — University of California, San Francisco
- Study coordinator: Acharya, Nisha
Related research
Other NIH-funded projects on the same topics.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.